Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2018 Aug 3;18(1):124.
doi: 10.1186/s12876-018-0848-1.

Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma

Yi-Sheng Liu  1 , Chia-Ying Lin  1 , Ming-Tsung Chuang  1 , Chia-Ying Lin  1 , Yi-Shan Tsai  1 , Chien-Kuo Wang  1 , Ming-Ching Ou  2
Affiliations
Observational Study

Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma

Yi-Sheng Liu et al. BMC Gastroenterol. .

Abstract

Background: Currently, no standard of care or therapies have been established for patients with advanced HCC. We evaluated the efficacy and safety of conventional transarterial chemoembolization using gelatin sponges or microspheres plus lipiodol-doxorubicin (cTACE) and TACE with doxorubicin-loaded drug eluting beads (DEB-TACE).

Methods: This retrospective study included 273 patients who received cTACE (n = 201) or DEB-TACE. Tumor response, survival, and adverse events were evaluated over a 5-year follow-up period.

Results: During 5-year follow-up, a greater percentage of patients treated with cTACE died than those treated with DEB-TACE (76.1% vs. 66.7%) (P = 0.045). At the last evaluation, all surviving patients had disease progression and no differences were seen between treatment groups. However, the time to disease progression differed between groups; median time to disease progression was 11.0 months for cTACE and 16.0 months for DEB-TACE (P = 0.019). The median survival time was 37 months in both treatment groups. No significant differences were observed between cTACE and DEB-TACE therapies in subgroups of patients with BCLC stage A or stage B + C either in survival time or time to disease progression (P values > 0.05). No significant differences were observed in survival status or disease progression between cTACE and DEB-TACE in patient subgroups with either tumor number > 5 or with the sum of the diameter of largest five HCC tumors being > 7 cm.

Conclusions: DEB-TACE demonstrates greater long-term benefits than cTACE in treating treatment-naïve patients with HCC. Results of this long-term study support the use of DEB-TACE in treating HCC.

Keywords: DEB-TACE; Drug-eluting bead transcatheter arterial chemoembolization; Hepatocellular carcinoma; TACE; Transcatheter arterial chemoembolization.

PubMed Disclaimer

Conflict of interest statement

The study was performed in accordance with the Declaration of Helsinki and the protocol was reviewed and approved by the Institutional Review Board of the hospital. All patients provided signed informed consent.

Not applicable.

The authors declare that they have no competing interests.

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Kaplan-Meier curve of overall survival time (a) and PFS time (b) by treatments. a The estimated median overall survival time was derived as 37 months (95%CI = 32.2–41.8 months) for cTACE and 37 months (95%CI = 23.5–50.5 months) for DEB-TACE. The log-rank test p-value = 0.091. b The estimated median PFS time was derived as 11 months (95%CI = 9.6–12.4 months) for cTACE and 16 months (95%CI = 13.1–18.9 months) for DEB-TACE. The log-rank test p-value = 0.019
See this image and copyright information in PMC

References

    1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90. doi: 10.3322/caac.20107. - DOI - PubMed
    1. Thomas MB, Jaffe D, Choti MM, Belghiti J, Curley S, Fong Y, et al. Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute clinical trials planning meeting. J Clin Oncol. 2010;28(25):3994–4005. doi: 10.1200/JCO.2010.28.7805. - DOI - PMC - PubMed
    1. Bruix J, Sherman M. American Association for the Study of liver D. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020–1022. doi: 10.1002/hep.24199. - DOI - PMC - PubMed
    1. European Association For The Study Of The L. European Organisation For R. Treatment Of C EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908–943. doi: 10.1016/j.jhep.2011.12.001. - DOI - PubMed
    1. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379(9822):1245–1255. doi: 10.1016/S0140-6736(11)61347-0. - DOI - PubMed

Publication types